Earning Analysis
Welcome to our in-depth analysis of Entrada Therapeutics Inc(TRDA) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Entrada Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q3 | 2024-11-05 | - | -0.67 | - | - | 11.88M | 19.57M | +64.80 | +4.78 | +11.93 |
| FY2024Q1 | 2024-05-07 | - | -0.38 | 0.68 | +278.95 | 15.19M | 59.12M | +289.09 | +2.81 | +4.07 |
| FY2023Q4 | 2024-03-13 | - | -0.07 | -0.29 | -314.29 | 23.70M | 41.85M | +76.61 | +9.76 | +9.67 |
| FY2023Q3 | 2023-11-07 | - | -0.55 | 1.02 | +285.45 | 9.60M | 43.74M | +355.69 | +8.63 | +4.80 |
| FY2023Q2 | 2023-08-08 | - | -0.43 | -0.78 | -81.40 | 9.78M | 18.17M | +85.86 | +10.47 | +10.19 |
| - | 2023-05-10 | - | -0.77 | -0.21 | +72.73 | - | - | - | -2.13 | +7.30 |
| - | 2023-03-06 | - | -0.84 | -0.79 | +5.95 | - | - | - | -1.41 | +14.49 |
TRDA Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Entrada Therapeutics Inc reported performance for FY2024Q3, announced on 2024-11-05. The company achieved an EPS of , compared to analyst estimates of -0.67 by % . Revenue for the quarter reached 19.57M compared to expectations of 11.88M by 64.80% .
The stock price reacted with a 4.78% one-day change and a 11.93% five-day change following the earnings release. These movements reflect market reaction in Entrada Therapeutics Inc growth trajectory and strategic initiatives.
TRDA Earnings Forecast
Looking ahead, Entrada Therapeutics Inc(TRDA) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 8.49M and an EPS of -0.95.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -4.25%, while EPS estimates have been Revise Downward by -6.2%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 87.62% . These revisions correlate with a 92.06% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Entrada Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TRDA's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-4.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-6.2%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+87.62%
In Past 3 Month
Stock Price
Go Up
+92.06%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:32.61M
--
EPS Estimate-Annual FY 2025:-3.37
—
Stock Price10.16
TRDA Revenue and EPS Performance: A Historical Perspective
Entrada Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q3 (2024-11-05,):
EPS: (Actual) vs.-0.67 (Estimate) (%)
Revenue: 19.57M (Actual) vs. 11.88M (Estimate) (64.80%)
Price Reaction: 4.78%(1-Day), 11.93%(5-Day)
FY2024Q1 (2024-05-07,):
EPS: 0.68 (Actual) vs.-0.38 (Estimate) (278.95%)
Revenue: 59.12M (Actual) vs. 15.19M (Estimate) (289.09%)
Price Reaction: 2.81%(1-Day), 4.07%(5-Day)
FY2023Q4 (2024-03-13,):
EPS: -0.29 (Actual) vs.-0.07 (Estimate) (-314.29%)
Revenue: 41.85M (Actual) vs. 23.70M (Estimate) (76.61%)
Price Reaction: 9.76%(1-Day), 9.67%(5-Day)
Earnings Reaction
The chart below shows how TRDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TRDA sees a +1.15% change in stock price 10 days leading up to the earnings, and a +10.58% change 10 days following the report. On the earnings day itself, the stock moves by +4.70%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2024, the stock changed 0.21% on the day following the earnings release and then changed by -4.56% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
No Data
People Also Watch
FAQ
What were the key highlights of TRDA’s latest earnings report for FY2024Q3?
How did TRDA’s stock price react after the FY2024Q3 earnings release?
What are the revenue and EPS estimates for TRDA for 2025/Q4?
How does TRDA’s stock price correlate with earnings forecast revisions?
What should investors expect from TRDA’s next earnings report?